- Company
- KRPIA and members clash over Sean Kim’s resignation
- by Eo, Yun-Ho Apr 16, 2020 06:36am
- Apparently, the multinational pharmaceutical companies in Korea have disputed KRPIA’s approval on the resignation of Senior Director Sean Kim. The pharmaceutical industry sources reported Sean Kim, a Senior Director of Market Access and Healthcare Policy at Korean Research-based Pharmaceutical Industry Association (KRPIA), has expressed
- Company
- KRW 2 trillion worth damage by COVID-19 to hit drug industry
- by Nho, Byung Chul Apr 16, 2020 06:33am
- Impacted by COVID-19 outbreak, Korean pharmaceutical industry requested the government for an emergency initiative like new pharmaceutical regulatory policy to avoid a total dissolution of the Korean pharmaceutical and bio industry. The industry has requested the government to halt the new pharmaceutical regulatory policy but to reinforc
- Company
- Janssen's Vaccines has no annual sales in 10 years
- by An, Kyung-Jin Apr 16, 2020 06:33am
- Janssen Vaccines, which once generated annual sales of ￦300 billion through vaccine manufacturing and sales, recorded zero in sales last year. As demand for representative products, which were responsible for the company's sales, fell sharply, sales activities were virtually suspended. After the withdrawal of the Hyangnam factory in 2021,
- Company
- Drug companies and distributors conflicted over margin
- by Jung, Hye-Jin Apr 16, 2020 06:32am
- As more and more pharmaceutical companies are lowering distribution margin to save cost, a conflict between pharmaceutical companies and distributors is left unresolved. Although the two parties are continuing to negotiate on appropriate distribution margin, they end up only confirming their unyielding stances. Recently, a number of Korea
- Company
- KDA finally agrees on SGLT2 inhibitor benefits
- by Eo, Yun-Ho Apr 14, 2020 06:15am
- The Korean Diabetes Association (KDA) has finally reached an agreement on expanding reimbursement on sodium-glucose transport protein 2 (SGLT2) inhibitor combination therapy. KDA has submitted a statement to the Korean government regarding the needs of expanded coverage on SGLT2 inhibitor plus off-label diabetes treatments, including dipe
- Company
- KPBMA “Exempt transferred originals from pricing reduction"
- by Eo, Yun-Ho Apr 14, 2020 06:12am
- All of pharmaceutical industry is responding against the risk in pricing reduction on original drugs transferred due to a split-off. Pharmaceutical industry sources reported, Korea Pharmaceutical and Bio-pharma Manufacturers Association (KPBMA) plans to deliver an official statement to the health authority demanding the government to exem
- Company
- Roche’s ADC Kadcyla retries coverage on early breast cancer
- by Eo, Yun-Ho Apr 10, 2020 06:28am
- Roche is reapplying for Kadcyla’s expanded reimbursement on its early-stage breast cancer indication. According to pharmaceutical industry sources, Roche has recently submitted an application for additional reimbursement on antibody-drug conjugate (ADC) Kadcyla (trastuzumab emtansine). The reimbursement expansion is on the indication a
- Company
- Novartis Korea recorded the largest sales last year
- by An, Kyung-Jin Apr 10, 2020 06:28am
- Novartis Korea recorded the largest sales last year. The first time since the launch of Korea, the sales of representative medicines and new drugs have reached &8361;500 billion. According to Novartis Korea's audit report submitted to the Financial Supervisory Service on the 8th, the company's sales last year were &8361;493.4 billion,
- Company
- Yuhan receives KRW 43 bln for first lazertinib milestone
- by An, Kyung-Jin Apr 10, 2020 06:28am
- On Apr. 8, Yuhan has announced Janssen Biotech would pay out USD 35 million (approximately 43 billion won) to the Korean pharmaceutical company for the licensed out lazertinib’s first milestone. The lazertinib pipeline has reached the first development milestone as clinical study on a combination therapy with Janssen’s anticancer medic
- Company
- Social distance postponed tax investigations
- by Nho, Byung Chul Apr 9, 2020 06:26am
- In order to prevent the spread of COVID-19, tax investigations by some pharmaceutical companies in progress are reportedly delayed. According to the industry, Daewoong Bio, Bayer Korea, and Hanmi Pharm are currently under investigation by the National Tax Service. This survey is believed to be a regular tax investigation, not a special tax
